Gemopatrilat (INN)[1] is an experimental drug that was never marketed.

[2] It acts as a vasopeptidase inhibitor.

[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).

[5] This drug article relating to the cardiovascular system is a stub.

You can help Wikipedia by expanding it.